SCHEDULE APPOINTMENT: CALL 800.999.1249 OR SCHEDULE ONLINE
AstraZeneca (ACADIA) Mild to Severe Asthma Study
If you are interested in participating and believe you meet the requirements, please contact our research staff to learn more at 502.368.0732.
- Home >
- About >
- Research Institute >
- Current Research Studies >
- AstraZeneca (ACADIA) Mild to Severe Asthma Study
ASTRAZENECA (ACADIA) AGES 12 TO 17 YEARS (MILD TO SEVERE ASTHMA STUDY)
- This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.
- The purpose of this study is to compare BDA MDI with AS MDI on the severe asthma exacerbations in adolescent participants aged 12 to < 18 years with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
- The anticipated duration of the study is approximately 58 weeks, including a 1 to 4 week screening period, followed by a 52 week treatment period, and a 1 to 2 week follow-up period. The total number of visits is between 8 and 10, including visits during the treatment period of every 4 weeks up until 12 weeks and then every 12 weeks until 36 weeks of treatment period followed by EOT visit (Week 52).
- BDA MDI delivers the bronchodilatory effects of albuterol and the anti-inflammatory effects of budesonide in the most widely used inhalation device for the treatment of asthma.
Key Inclusion Criteria:
- Participant must be 12 to < 18 years at screening Visit 1.
- Confirmed clinical diagnosis of asthma at least 12 months before Visit 1.
- Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month before Visit 1: Low-to-high-dose ICS or Low-to-high-dose ICS or ICS/LABA with or without one additional maintenance therapy from the following: LTRA, LAMA, or theophylline
Key Exclusion Criteria:
- Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months before Visit 1 (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
- Other significant lung disease (eg, chronic bronchitis, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia), including regular or occasional use of oxygen.
Interested in This Research Study?
If you’d like to learn more or see whether you may be eligible to participate, please complete the brief interest form below. A member of our research team will follow up with next steps.
Research Study Interest Form
To learn more or express interest in this study, please complete the form below or contact our research team at 502-368-0732.
